CEO: John M. Maraganore

Sector: Healthcare
Industry:Biotechnology

Exchange: Nasdaq Global Select

Country: USA

Description: Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.


Key numbers

Market Capitalization:10262654500
Shares Outstanding: 111490000
Float: 110286465.44999999
Next Earning Date:2020-02-06
TTm EPS: -7.7579
TTm Dividend Rate:
200 days moving average:80.54
50 days moving average: 84.87
One day percent Change: 1.76



2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31,
2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,